Text Size

Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

This study has been completed.
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00678028
First received: February 17, 2008
Last updated: April 22, 2009
Last verified: April 2009
History of Changes
  Purpose

Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.


Condition
Recurrent Urinary Tract Infections

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Biospecimen Retention:   Samples With DNA

whole blood for genetic test and serum for MBL test


Estimated Enrollment: 200
Study Start Date: February 2008
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

young women with recurrent UTI - study group and young women witout recurrent UTI - a control group

Criteria

Inclusion Criteria:

  • women above 18 years old.
  • premenopausal
  • recurrent UTI

Exclusion Criteria:

  • pregnancy
  • immunocompromised
  • active malignancy
  • HIV carrier
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00678028

Locations
Israel
Ha'Emek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

No publications provided

Responsible Party: Dr. Orna Nitzan, Ha'emek Medical Center, Afula, Israel
ClinicalTrials.gov Identifier: NCT00678028     History of Changes
Other Study ID Numbers: 0080-07-EMC
Study First Received: February 17, 2008
Last Updated: April 22, 2009
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by HaEmek Medical Center, Israel:
MBL, UTI

Additional relevant MeSH terms:
Urinary Tract Infections
Infection
Urologic Diseases

ClinicalTrials.gov processed this record on May 16, 2013